Anthony Kosisochukwu Anyabuoke
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Anthony Kosisochukwu Anyabuoke has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Blessing Chinonye Nwadike
Department of Medical Laboratory Science, Faculty of Health Science, Imo State University, Owerri, Imo State, Nigeria
2 shared publications - Adebola Ayisat Effa
Department of Product Development and Quality Assurance, Nigeria Natural Medicine Development Agency, Lagos, Nigeria
1 shared publication - Bassey Atte Inyang
Department of Medical Biochemistry, College of Health Sciences, University of Abuja, FCT, Nigeria
1 shared publication - Comfort Ohunene Matthew
Department of Clinical Pharmacy, Faculty of Pharmacy, University of Benin, Benin City, Nigeria
1 shared publication - Daniel Obinna Eke
Department of Nursing, Myrtle E. and Earl E. Walker College of Health Professions Maryville University of St. Louis, St. Louis, MO, USA
1 shared publication - Ejembi Bright
Department of Medicine and Surgery, University of Jos, Jos, Nigeria
1 shared publication
Latest Publications
- Open Access
- 30 August 2026
- Published by Australasia Publishing Group in Epidemiology and Health Data Insights
- Vol. 2 (5) , ehdi054
Exploring the Potential of CRISPR-Cas9 Gene Editing for Sickle Cell Disease and Malaria Resistance: A Systematic Review
Background: Sickle cell disease (SCD) and malaria remain major health challenges in sub-Saharan Africa. CRISPR-Cas9 has enabled advances in SCD gene therapy and malaria-related experimental research, but these applications represent distinct biological and translational pathways. This systematic review evaluated CRISPR-Cas9 applications in SCD and malaria research while distinguishing clinical therapeutic evidence from experimental malaria-related findings. Methods: A systematic review was conducted following PRISMA 2020 and Joanna Briggs Institute guidance. PubMed, ScienceDirect and Google Scholar were searched on 12 August 2026. Studies investigating CRISPR-Cas9 applications related to SCD or malaria, including HBBcorrection, fetal haemoglobin induction, host-cell modification, parasite genome editing and mosquito-vector modification, were included. Data were synthesised narratively due to substantial heterogeneity among study designs and outcomes. Results: Thirteen studies were included, comprising six SCD-related and seven malaria-related studies. SCD studies demonstrated progression from experimental genome correction and haemoglobin regulation strategies to clinical application of CRISPR-edited autologous haematopoietic stem and progenitor cells. Malaria-related studies primarily investigated parasite functional genomics, erythrocyte invasion mechanisms and mosquito genetic modification. No included study evaluated a single CRISPR-Cas9 intervention that simultaneously treated SCD and enhanced malaria resistance. Conclusion: CRISPR-Cas9 represents an advancing therapeutic platform for selected SCD applications and an important experimental tool in malaria research. Current evidence supports separate translational pathways, with clinical progress established in SCD and malaria applications remaining predominantly preclinical.
- 30 August 2026
- Published by Australasia Publishing Group in Epidemiology and Health Data Insights
- Vol. 2 (5) , ehdi054
Open AccessExploring the Potential of CRISPR-Cas9 Gene Editing for Sickle Cell Disease and Malaria Resistance: A Systematic Review
Background: Sickle cell disease (SCD) and malaria remain major health challenges in sub-Saharan Africa. CRISPR-Cas9 has enabled advances in SCD gene therapy and malaria-related experimental research, but these applications represent distinct biological and translational pathways. This systematic review evaluated CRISPR-Cas9 applications in SCD and malaria research while distinguishing clinical therapeutic evidence from experimental malaria-related findings. Methods: A systematic review was conducted following PRISMA 2020 and Joanna Briggs Institute guidance. PubMed, ScienceDirect and Google Scholar were searched on 12 August 2026. Studies investigating CRISPR-Cas9 applications related to SCD or malaria, including HBBcorrection, fetal haemoglobin induction, host-cell modification, parasite genome editing and mosquito-vector modification, were included. Data were synthesised narratively due to substantial heterogeneity among study designs and outcomes. Results: Thirteen studies were included, comprising six SCD-related and seven malaria-related studies. SCD studies demonstrated progression from experimental genome correction and haemoglobin regulation strategies to clinical application of CRISPR-edited autologous haematopoietic stem and progenitor cells. Malaria-related studies primarily investigated parasite functional genomics, erythrocyte invasion mechanisms and mosquito genetic modification. No included study evaluated a single CRISPR-Cas9 intervention that simultaneously treated SCD and enhanced malaria resistance. Conclusion: CRISPR-Cas9 represents an advancing therapeutic platform for selected SCD applications and an important experimental tool in malaria research. Current evidence supports separate translational pathways, with clinical progress established in SCD and malaria applications remaining predominantly preclinical.
- 26 June 2026
- Published by Australasia Publishing Group in Oncology, Nuclear Medicine and Transplantology
- Vol. 2 (2) , onmt020
Tumor–Immune Interactions in Prostate Cancer: Insights from Single-Cell and Spatial Genomics
Prostate cancer still remains one of the most common cancers in men worldwide, and it is a great therapeutic challenge, especially in the field of immunotherapeutics. The tumour microenvironment (TME) is immunologically “cold” in prostate cancer, and influenced by intrinsic molecular characteristics of the disease such as androgen receptor (AR) signalling, PTEN loss, and lineage plasticity towards neuroendocrine prostate cancer (NEPC). Together, these aspects inhibit antigen presentation, block the entry of cytotoxic T cells and help to establish spatially organised immunosuppressive niches, providing a rational explanation for the clinical variability and partial efficacy of immune-based therapies. Traditional bulk genomic approaches have provided important insights into tumour biology but are unable to capture the cellular and spatial complexity of tumour–immune interactions. These developments have been spurred by recent advancements in single-cell RNA sequencing (scRNA-seq) and spatial transcriptomics, which allow to detect individual cell subpopulations within intact tumour tissues, such as exhausted T cells co-expressing PD-1, TIM-3, LAG-3 and TIGIT, immunosuppressive SPP1+ macrophages and various cancer-associated fibroblast subpopulations. These technologies have identified specific immune exclusion sites, stromal–epithelial immune silencing barriers, and therapeutic resistance and immune evasion regulatory programs in the context of prostate cancer specifically. However, there are still many technical challenges that need to be overcome, such as the lack of patient samples and their demographic diversity, data integration, lack of spatial characterisation of bone metastases and difficulties in clinical translation. Comprehensive multi-omics atlases, AI-driven spatial pattern recognition, functional validation of potential targets and prospective clinical trials based on biomarkers are all important areas for future research. They show significant potential for the creation of better, personalized immunotherapeutic treatment for prostate cancer.
- 26 June 2026
- Published by Australasia Publishing Group in Oncology, Nuclear Medicine and Transplantology
- Vol. 2 (2) , onmt020
Tumor–Immune Interactions in Prostate Cancer: Insights from Single-Cell and Spatial Genomics
Prostate cancer still remains one of the most common cancers in men worldwide, and it is a great therapeutic challenge, especially in the field of immunotherapeutics. The tumour microenvironment (TME) is immunologically “cold” in prostate cancer, and influenced by intrinsic molecular characteristics of the disease such as androgen receptor (AR) signalling, PTEN loss, and lineage plasticity towards neuroendocrine prostate cancer (NEPC). Together, these aspects inhibit antigen presentation, block the entry of cytotoxic T cells and help to establish spatially organised immunosuppressive niches, providing a rational explanation for the clinical variability and partial efficacy of immune-based therapies. Traditional bulk genomic approaches have provided important insights into tumour biology but are unable to capture the cellular and spatial complexity of tumour–immune interactions. These developments have been spurred by recent advancements in single-cell RNA sequencing (scRNA-seq) and spatial transcriptomics, which allow to detect individual cell subpopulations within intact tumour tissues, such as exhausted T cells co-expressing PD-1, TIM-3, LAG-3 and TIGIT, immunosuppressive SPP1+ macrophages and various cancer-associated fibroblast subpopulations. These technologies have identified specific immune exclusion sites, stromal–epithelial immune silencing barriers, and therapeutic resistance and immune evasion regulatory programs in the context of prostate cancer specifically. However, there are still many technical challenges that need to be overcome, such as the lack of patient samples and their demographic diversity, data integration, lack of spatial characterisation of bone metastases and difficulties in clinical translation. Comprehensive multi-omics atlases, AI-driven spatial pattern recognition, functional validation of potential targets and prospective clinical trials based on biomarkers are all important areas for future research. They show significant potential for the creation of better, personalized immunotherapeutic treatment for prostate cancer.
- 5 May 2026
- Published by Australasia Publishing Group in Oncology, Nuclear Medicine and Transplantology
- Vol. 2 (2) , onmt018
Cancer-Specific Disproportionality Signals Associated with Metformin Versus Other Antidiabetic Agents: A Real-World Pharmacovigilance Analysis of FAERS
Type 2 diabetes mellitus is associated with an increased risk of several malignancies, prompting interest in the potential oncologic effects of antidiabetic therapies, particularly metformin. This study evaluated cancer-related adverse event reporting associated with metformin compared with other antidiabetic agents using real-world pharmacovigilance data from the FDA Adverse Event Reporting System (FAERS) between Q1 2023 and Q4 2024. A disproportionality analysis was conducted on over 3.2 million reports, including 66,187 metformin cases and 55,257 comparator cases comprising GLP-1 receptor agonists, SGLT2 inhibitors, sulfonylureas, and insulin. Reporting odds ratios (ROR), proportional reporting ratios (PRR), information components (IC), and chi-squared tests were applied across twelve pre-specified cancer types. Metformin was associated with significantly lower reporting of hepatocellular carcinoma (ROR 0.377, 95% CI 0.181–0.782) and pancreatic carcinoma (ROR 0.669, 95% CI 0.493–0.908). In contrast, increased reporting signals were observed for prostate cancer (ROR 2.065, 95% CI 1.435–2.972), leukaemia (ROR 2.388, 95% CI 1.155–4.939), and breast cancer (ROR 1.404, 95% CI 1.023–1.926). Drug-specific comparisons indicated relatively lower overall cancer reporting for metformin compared with sitagliptin and empagliflozin, but higher reporting compared with insulin. Temporal analyses demonstrated variability in reporting patterns across study quarters. These findings represent disproportionality signals reflecting reporting associations rather than causal effects and may be influenced by reporting bias, residual confounding, and differences in healthcare utilization. Overall, the results suggest a heterogeneous, cancer-type-specific reporting profile for metformin and highlight the value of pharmacovigilance analyses in generating real-world safety signals. Further confirmation in prospective and mechanistic studies is required.
- 5 May 2026
- Published by Australasia Publishing Group in Oncology, Nuclear Medicine and Transplantology
- Vol. 2 (2) , onmt018
Cancer-Specific Disproportionality Signals Associated with Metformin Versus Other Antidiabetic Agents: A Real-World Pharmacovigilance Analysis of FAERS
Type 2 diabetes mellitus is associated with an increased risk of several malignancies, prompting interest in the potential oncologic effects of antidiabetic therapies, particularly metformin. This study evaluated cancer-related adverse event reporting associated with metformin compared with other antidiabetic agents using real-world pharmacovigilance data from the FDA Adverse Event Reporting System (FAERS) between Q1 2023 and Q4 2024. A disproportionality analysis was conducted on over 3.2 million reports, including 66,187 metformin cases and 55,257 comparator cases comprising GLP-1 receptor agonists, SGLT2 inhibitors, sulfonylureas, and insulin. Reporting odds ratios (ROR), proportional reporting ratios (PRR), information components (IC), and chi-squared tests were applied across twelve pre-specified cancer types. Metformin was associated with significantly lower reporting of hepatocellular carcinoma (ROR 0.377, 95% CI 0.181–0.782) and pancreatic carcinoma (ROR 0.669, 95% CI 0.493–0.908). In contrast, increased reporting signals were observed for prostate cancer (ROR 2.065, 95% CI 1.435–2.972), leukaemia (ROR 2.388, 95% CI 1.155–4.939), and breast cancer (ROR 1.404, 95% CI 1.023–1.926). Drug-specific comparisons indicated relatively lower overall cancer reporting for metformin compared with sitagliptin and empagliflozin, but higher reporting compared with insulin. Temporal analyses demonstrated variability in reporting patterns across study quarters. These findings represent disproportionality signals reflecting reporting associations rather than causal effects and may be influenced by reporting bias, residual confounding, and differences in healthcare utilization. Overall, the results suggest a heterogeneous, cancer-type-specific reporting profile for metformin and highlight the value of pharmacovigilance analyses in generating real-world safety signals. Further confirmation in prospective and mechanistic studies is required.